• @kassem
    Kassem CC BY-NC-SA

    Ici une étude qui trouve une mortalité nettement diminuée lors de l’emploi d’anticoagulants chez les patients #COVID-19 sous intubation avec ventilation assistée.

    Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19 | JACC : Journal of the American College of Cardiology
    ▻http://www.onlinejacc.org/content/early/2020/05/05/j.jacc.2020.05.001

    In patients who required mechanical ventilation (N=395), in-hospital mortality was 29.1% with a median survival of 21 days for those treated with AC as compared to 62.7% with a median survival of 9 days in patients who did not receive AC (Figure 1B). In a multivariate proportional hazards model, longer duration of AC treatment was associated with a reduced risk of mortality (adjusted HR of 0.86 per day, 95% confidence interval 0.82-0.89, p<0.001).

    Kassem CC BY-NC-SA
    • @kassem
      Kassem CC BY-NC-SA

      MGH FLARE - May 8 - New observational reports on anticoagulation and immunomodulation
      ►https://mailchi.mp/788aa3f42e35/tz4idnzryr-4420565?e=06f3eb75c2

      Cette analyse du MGH repasse en revue les tres nombreux #biais de l’étude avant de conclure qu’elle ne permet pas du tout de conclure à l’utilité des anticoagulants dans la population ciblée.

      (les passages en gras sont d’origine)

      Treatment decisions regarding anticoagulation should not be made based on these data . As the authors appropriately note, only a well-designed randomized control trial can offer definitive data on drug efficacy. The paper by Paranjpe and colleagues has methodological flaws which can result in misleading conclusions. We do not believe these data provide interpretable answers to the question of interest — the therapeutic role of anticoagulation in patients with COVID-19.

      Kassem CC BY-NC-SA
    Écrire un commentaire